Remdesivir bụ ọgwụ mgbochi nje na-elekwasị anya n'ọtụtụ nje. Emebere ya ihe karịrị afọ iri gara aga iji gwọọ ịba ọcha n'anya C na nje oyi yiri nke a na-akpọ virus syncytial respiratory (RSV). Remdesivir abụghị ọgwụgwọ dị mma maka ọrịa abụọ ahụ. Mana o gosipụtara nkwa megide nje ndị ọzọ.

Ndị nyocha nwalere remdesivir na nnwale ụlọ ọgwụ n'oge ntiwapụ Ebola. Ọgwụ nyocha ndị ọzọ na-arụ ọrụ nke ọma, mana egosiri na ọ dị mma maka ndị ọrịa. Nnyocha na mkpụrụ ndụ na anụmanụ tụrụ aro na remdesivir dị irè megide nje na ezinụlọ coronavirus, dị ka Middle East Respiratory Syndrome (MERS) na Severe Acute Respiratory Syndrome (SARS).

Remdesivir na-arụ ọrụ site n'ịkwụsị mmepụta nke nje. Coronaviruses nwere genome mebere ribonucleic acid (RNA). Remdesivir na-etinye aka na otu n'ime isi enzymes nke nje a chọrọ iji megharịa RNA. Nke a na-egbochi nje ahụ ịmụba.

Ndị ọrụ nyocha bidoro nnwale a na-achịkwaghị achịkwa nke mgbochi nje na February 2020 iji nwalee ma enwere ike iji remdesivir gwọọ SARS-CoV-2, coronavirus na-akpata COVID-19. Ka ọ na-erule Eprel,nsonaazụ mbụgosiri na remdesivir na-agbake ngwa ngwa maka ndị ọrịa nọ n'ụlọ ọgwụ nwere nnukwu COVID-19. Ọ ghọrọ ọgwụ izizi nwetara ikike iji ihe mberede sitere na nchịkwa nri na ọgwụ US (FDA) iji gwọọ ndị COVID-19 nọ n'ụlọ ọgwụ.

Ndị nyocha emechaala nnwale a, nke a maara dị ka nnwale ọgwụgwọ COVID-19 Adaptive (ACTT-1). Ụlọ ọrụ National Institute of Allergy and Infectious Diseases (NIAID) kwadoro ọmụmụ ihe ahụ. Akụkọ ikpeazụ pụtara naAkwụkwọ akụkọ Ọgwụ nke New Englandna Ọktoba 8, 2020.